![](/imager/uploads/Companies/Alchemab/40838/IAC0288_6439e647a38ed5b4d852739476ebaac9.webp)
![](/uploads/logos/_logo_h/alchemab-logo-black.png)
People who beat cancer, or have neurodegenerative conditions that are very slow to progress, may harbor naturally occurring protective antibodies that make them more resilient against these devastating diseases. Alchemab sequences the B cells of these individuals, uses AI to identify groups of related antibodies across the resilient population, finds the binding targets of these antibodies, and uses that information to design treatments that could help other patients fight solid tumors, infections, or Alzheimer’s.
In The Media
Explore Companies
![](/imager/uploads/logos/58681/Avicenna_logo_black_117378e58441a39758ec294c229f7090.webp)
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery
![](/imager/uploads/logos/58643/latus-logo-copy_117378e58441a39758ec294c229f7090.webp)
![](/imager/uploads/Companies/Latus/58650/Latus-lab_6439e647a38ed5b4d852739476ebaac9.webp)
Latus Bio
Finding precisely tuned viral vectors for gene therapy in CNS disorders
![](/imager/uploads/logos/57002/radionetics-logo_black_117378e58441a39758ec294c229f7090.webp)
![](/imager/uploads/Companies/Radionetics/57003/Radionetics_6439e647a38ed5b4d852739476ebaac9.webp)
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
![](/imager/uploads/logos/55895/DVLP-logo-black_117378e58441a39758ec294c229f7090.webp)
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing